Faster start for XR-naltrexone improves opioid use disorder treatment

Summary: A clinical trial supported by NIH's NIDA found starting opioid use disorder patients on XR-naltrexone within 5-7 days of seeking treatment is more effective than the standard 10-15 days. The rapid approach increased first injections by 62.7% compared to 35.8%. The study, SWIFT, aimed to make XR-naltrexone more viable as an opioid use disorder treatment option. Over 107,000 people died of drug overdoses in 2022, with 75% involving opioids.

Full article